Results 111 to 120 of about 137,826 (378)

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Rad62 protein functionally and physically associates with the Smc5/Smc6 protein complex and is required for chromosome integrity and recombination repair in fission yeast [PDF]

, 2004
Smc5 and Smc6 proteins form a heterodimeric SMC (structural maintenance of chromosome) protein complex like SMC1-SMC3 cohesin and SMC2-SMC4 condensin, and they associate with non-SMC proteins Nse1 and Nse2 stably and Rad60 transiently.
Carr, Antony, Iwasaki, H., Kawane, S., Morikawa, H., Morishita, Takashi, Shinagawa, H.   +5 more
core   +2 more sources

Analysis of homologous recombination deficiency in prostate cancer

Сибирский онкологический журнал
Background. Mutations in homologous recombination repair (HRR) genes (BRCA2, ATM, CHEK2, NBN, etc.) are found in 20–25 % of patients with metastatic prostate cancer (PC) and are an indication for prescription of PARP inhibitors.
A. G. Iyevleva, S. N. Aleksakhina, A. P. Sokolenko, E. A. Otradnova, A. S. Nikitina, K. A. Kashko, M. V. Syomina, N. S. Morozova, A. D. Shestakova, E. Sh. Kuligina, E. N. Imyanitov   +10 more
doaj   +1 more source

Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review

Asian Journal of Oncology, 2019
Poly (ADP-ribose) polymerase (PARP) inhibitors are a unique class of therapeutic agents that focus on tumors with deficiencies in the homologous recombination DNA repair mechanism.
Vikas Goswami, Venkata Pradeep Babu Koyyala, Sumit Goyal, Manish Sharma, Varun Goel, Nilesh Dhamne, Udip Maheshwari, Atul Sharma   +7 more
doaj   +1 more source

DirectHRD enables sensitive scar-based classification of homologous recombination deficiency. [PDF]

Nucleic Acids Res
Homologous recombination deficiency (HRD) is a predictive biomarker for efficacy of PARP inhibition and platinum chemotherapy but remains challenging to detect from low tumor fraction samples such as liquid biopsies. Here, we describe DirectHRD, a whole-genome sequencing (WGS) scar-based classifier that is 10x more sensitive than state-of-the-art ...
Liu R, Roberts E, Parsons HA, Stover EH, Choudhury AD, Rhoades J, Blewett T, Yang DD, Liu JF, Mayer EL, Adalsteinsson VA.   +10 more
europepmc   +3 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]

, 2015
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T, BENEDETTI PANICI, PIERLUIGI, CASORELLI, ASSUNTA, DI DONATO, VIOLANTE, DOMENICI, LAVINIA, GASPARRI, MARIALUISA, IMPERIALE, LUDOVICA, MARCHETTI, CLAUDIA, MONTI, Marco, MUSELLA, ANGELA, MUZII, LUDOVICO, PALAIA, INNOCENZA, PECORINI, Francesco, RUSCITO, ILARY, SALERNO, LAURA   +14 more
core   +1 more source

Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)

BMC Medicine, 2022
Intraductal carcinoma of the prostate (IDC-P) is a subtype of prostate cancer featured by poor prognosis. Previous studies suggested IDC-P could have a potentially unstable genome.
Sha Zhu, Jinge Zhao, L. Nie, Wenlian Yin, Yaowen Zhang, Fengnian Zhao, Y. Ni, Xingming Zhang, Zhipeng Wang, Jindong Dai, Zhenhua Liu, Junru Chen, Yuhao Zeng, Zilin Wang, G. Sun, Jiayu Liang, Xiaochen Zhao, Xudong Zhu, Ronggui Tao, Jiyu Yang, Ben He, N. Chen, P. Shen, H. Zeng   +23 more
semanticscholar   +1 more source

The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress [PDF]

, 2015
The MRE11/RAD50/NBS1 (MRN) complex is a major sensor of DNA double strand breaks, whose role in controlling faithful DNA replication and preventing replication stress is also emerging. Inactivation of the MRN complex invariably leads to developmental and/
A Dupre, A Gulino, A Kuzyk, A Shibata, A Soriani, A Wey, A Wey, AM Duursma, AM Taylor, B Argenti, B Ricci, B Shiotani, BR Stanton, C Bruhn, C Heil, CJ Thiele, CL Marcelis, D Dominguez-Sola, D Fruci, DW Felsher, EA Rahal, F Sardina, G Giannini, G Giannini, H van Bokhoven, HE Bryant, I Screpanti, J Buis, J Charron, J Lafrance-Vanasse, J Wu, K Schlacher, K Trenz, KA Cole, KH Chrzanowska, KK To, L Di Marcotullio, LJ Valentijn, M Cognet, M Murga, M Petroni, M Petroni, M Sahún-Roncero, M Wilda, M Wojewodzka, O Chayka, P Khongkow, PE Neiman, PJ Hurlin, PO Frappart, PS Knoepfler, R Moser, R Thompson, R Waltes, RS Williams, RV Pusapati, S Albini, S Biton, S Ray, S Rohban, S Sawai, S Ying, SV Srinivasan, TG Oliver, TH Stracker, V Colicchia, V Veschi, V Veschi, W Lutz, YC Chiang, YL Lin   +70 more
core   +1 more source

Recurrent De Novo NAHR Reciprocal Duplications in the ATAD3 Gene Cluster Cause a Neurogenetic Trait with Perturbed Cholesterol and Mitochondrial Metabolism. [PDF]

, 2020
Recent studies have identified both recessive and dominant forms of mitochondrial disease that result from ATAD3A variants. The recessive form includes subjects with biallelic deletions mediated by non-allelic homologous recombination.
Armstrong, C, Baple, E, Baptista, J, Caswell, R, Cunningham, MH, Dean, J, Durigon, R, Durlacher-Betzer, K, Ellard, S, Fernandez Pelayo, U, Grochowski, CM, Gunning, AC, Harel, T, Holt, IJ, Homfray, T, Jones, AWE, Lahiri, N, Lupski, JR, Misra, VK, Muñoz Oreja, M, Parrish, A, Scurr, I, Spinazzola, A, Stals, KL, Strucinska, K, Taylor, RW, Tysoe, C, Wright, CF, Yoon, WH   +28 more
core   +3 more sources